Active surveillance vs radical prostatectomy

BJU International

Volumn 100, Issue SUPPL. 2, 2007, Pages 26-28

  Abrahamsson, Per Anders ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SCREENING; DISEASE SEVERITY; GLEASON SCORE; HUMAN; INCONTINENCE; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SEXUAL DYSFUNCTION; SHORT SURVEY;

HUMANS; MALE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 34250883933     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06949.x     Document Type: Short Survey

References (23)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005 16 : 481 8
2. Schersten T, Baile MA, Asua J, Jonsson E. Prostate Cancer Screening: Evidence Synthesis and Update (INAHTA Joint Project). Vitoria-Gasteiz: Basque Office for Health Technology Assessment. Health Department Basque Government (OSTEBA), 1999
3. Council of Europe. Recommendation No R(94)11 on screening as a tool of preventive medicine 1994. Available at: http://www.coe.Int/t/e/social_cohesion/ health/recommendations/Rec(1994)11.asp. Accessed April 2007
4. Johansson JE. Expectant management of early stage prostatic cancer: Swedish experience. J Urol 1994 152 : 1753 6
5. Chodak GW, Thisted RA, Gerber GS et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994 330 : 242 8
6. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55-74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998 280 : 975 80
7. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995 274 : 626 31
8. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002 137 : 917 29
9. Holmberg L, Bill-Axelson A, Helgesen F et al. Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002 347 : 781 9
10. Bill-Axelson A, Holmberg L, Ruutu M et al. Scandinavian Prostate Cancer Group Study No. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005 352 : 1977 84
11. Wilt TJ, Brawer MK. Early intervention or expectant management for prostate cancer. The Prostate Cancer Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with expectant management for the treatment of clinically localized prostate cancer. Semin Urol 1995 13 : 130 6
12. Donovan J, Hamdy F, Neal D et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 2003 7 : 1 88
13. Roemeling S, Roobol MJ, Postma R et al. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol 2006 50 : 475 82
14. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997 277 : 467 71
15. Brasso K, Friis S, Juel K, Jørgensen T, Iversen P. Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: a population based registry study. J Urol 1999 161 : 524 8
16. Aus G, Hugosson J, Norlén L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 1995 154 : 460 5
17. Sandblom G, Dufmats M, Varenhorst E. Long-term survival in a Swedish population-based cohort of men with prostate cancer. Urology 2000 56 : 442 7
18. Klotz L. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 2005 47 : 16 21
19. Klotz LH, Nam RK. Active surveillance with selective delayed intervention for favourable risk prostate cancer: clinical experience and a 'number needed to treat' analysis. Eur Urol Suppl 2006 5 : 479 86
20. Alibhai SMH, Leach M, Tomlinson G et al. 30-Day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst 2005 97 : 1525 32
21. Lu-Yao GL, Albertsen P, Warren J, Yao SL. Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy - a population-based study. Urology 1999 54 : 301 7
22. Slaughter P, Pinfold S, Laupacis A. Prostate-Specific Antigen (PSA) Screening in Asymptomatic Men. Toronto : Institute for Clinical Evaluative Sciences, 2002
23. Catalona WJ, Carvalhal GF, Mager DE, Smith DS. Potency, continence and complication rates in 1870 consecutive radical retropubic prostatectomies. J Urol 1999 162 : 433 8